Table 2 Electrophysiological variables on the baseline and 2, 5, 10, 15, 20, 30, 40, 50, 60, 90, 120, 150 and 180 minutes after serratus intercostal fascial plane block.

From: Assessment of cardiotoxicity and plasma ropivacaine concentrations after serratus intercostal fascial plane block in an experimental model

Parameter

Baseline

2 min-SIFPB

5 min-SIFPB

10 min-SIFPB

15 min-SIFPB

20 min-SIFPB

30 min-SIFPB

40 min-SIFPB

50 min-SIFPB

60 min-SIFPB

90 min-SIFPB

120 min-SIFPB

150 min-SIFPB

180 min-SIFPB

P

SCL (ms)

620 ± 113

612 ± 107

618 ± 114

615 ± 119

582 ± 106

590 ± 101

596 ± 130

589 ± 128

579 ± 120

595 ± 125

589 ± 102

560 ± 94

559 ± 80

550 ± 75

0.21

PR (ms)

112 ± 7

108 ± 10

109 ± 8

112 ± 11

108 ± 15

106 ± 15

100 ± 16

106 ± 11

106 ± 11

102 ± 15

103 ± 20

102 ± 23

108 ± 14

108 ± 12

0.33

QRS (ms)

71 ± 8

75 ± 9

76 ± 10

77 ± 8

74 ± 8

75 ± 9

78 ± 11

78 ± 8

79 ± 9

76 ± 9

74 ± 11

75 ± 12

77 ± 11

77 ± 10

0.15

StQRS400 (ms)

93 ± 12

–

99 ± 13

99 ± 16

97 ± 11

97 ± 9

94 ± 11

96 ± 8

94 ± 9

97 ± 10

95 ± 8

97 ± 9

96 ± 7

98 ± 8

0.35

StQRS500 (ms)

97 ± 10

–

96 ± 10

96 ± 9

97 ± 11

95 ± 10

97 ± 7

95 ± 8

97 ± 9

95 ± 11

95 ± 11

98 ± 11

99 ± 10

98 ± 11

0.53

QT (ms)

385 ± 30

385 ± 34

389 ± 32

390 ± 38

379 ± 32

388 ± 33

382 ± 50

382 ± 61

388 ± 50

389 ± 44

401 ± 45

398 ± 40

391 ± 40

405 ± 47

0.58

QTc (ms)

489 ± 30

492 ± 25

509 ± 40

497 ± 25

496 ± 32

507 ± 24

496 ± 23

504 ± 24

513 ± 26

505 ± 20

524 ± 40

531 ± 16

522 ± 17

544 ± 44

0.01

AH (ms)

77 ± 15

78 ± 7

83 ± 9

79 ± 11

81 ± 9

79 ± 11

74 ± 19

76 ± 13

78 ± 14

81 ± 11

81 ± 9

72 ± 12

81 ± 11

75 ± 12

0.43

HV (ms)

41 ± 7

37 ± 10

36 ± 9

38 ± 6

36 ± 7

35 ± 10

39 ± 7

35 ± 11

38 ± 7

35 ± 8

35 ± 7

39 ± 11

35 ± 7

36 ± 7

0.46

Ventricular threshold (mA)

0.20 (0.20–0.37)

–

0.25 (0.20–0.37)

0.35 (0.20–0.40)

0.35 (0.22–0.5)

0.35 (0.22–0.40)

0.35 (0.22–0.4)

0.35 (0.22–0.4)

0.4 (0.3–0.4)

0.3 (0.22–0.55)

0.3 (0.22–0.5)

0.3 (0.22–0.47)

0.3 (0.22–0.5)

0.35 (0.3–0.47)

0.14

Ropivacaine* (μg/ml)

0

1.33 ± 1.24

1.46 ± 1.31

2.15 ± 1.09

2 ± 1.05

2.28 ± 1.30

2.09 ± 1.23

1.97 ± 1.07

1.78 ± 0.98

1.73 ± 0.94

1.75 ± 0.98

1.68 ± 1.08

1.41 ± 0.94

1.41 ± 0.82

0.0001

  1. Data are shown as medians and interquartile range (IQR) for non-normally distributed data using the Shapiro–Wilk test, and as means ± standard deviation for normally distributed variables.
  2. SIFPB serratus intercostal fascial plane block, SCL sinus cycle length, PR PR interval, QRS QRS duration, St QRS400 duration of stimulated QRS at a paced cycle length of 400 ms, St QRS500 duration of stimulated QRS at a paced cycle length of 500 ms, QTc corrected QT interval, AH atrial His interval, HV His-ventricular interval.
  3. *Arterial ropivacaine concentrations.
Back to article page